Ectopic Pregnancy

Overview and Definition
Causes and Risk Factors
Symptoms
Diagnosis and the β-hCG Discriminatory Zone
Methotrexate Treatment
Surgical Treatment
Recovery and Supportive Care
Complications
Arias-Stella Reaction
Fertility After Ectopic Pregnancy
Prognosis
Key Research Papers
Connections
Featured Videos

Overview and Definition

An ectopic pregnancy occurs when a fertilized egg implants and begins to develop outside the uterine cavity. The fallopian tube is the most common site (95–98% of cases), with the ampullary segment (the widest portion) accounting for roughly 70% of tubal ectopics. Less common locations include the isthmus, fimbria, ovary, abdominal cavity, cervix, and — increasingly recognized — the cesarean-section scar.

Ectopic pregnancy affects approximately 2% of all pregnancies in the United States and is the leading cause of first-trimester maternal mortality, responsible for 6–9% of pregnancy-related deaths. The fallopian tube cannot sustain a growing pregnancy; left undiagnosed, it ruptures — typically between 6 and 10 weeks gestation — causing life-threatening intraabdominal hemorrhage. Advances in sensitive β-hCG assays and high-resolution transvaginal ultrasound now allow most ectopic pregnancies to be diagnosed before rupture.

Causes and Risk Factors

Any condition that impairs the orderly transport of the fertilized egg along the fallopian tube increases ectopic risk. Tubal damage from prior infection is the single most important modifiable risk factor.

Major Risk Factors

Prior pelvic inflammatory disease (PID) — the most significant risk factor; a single PID episode increases ectopic risk 6–10-fold by causing tubal scarring, ciliation loss, and adhesions that impede embryo transport
Prior ectopic pregnancy — recurrence risk is 10–15% after one ectopic and approaches 25–30% after two
Prior tubal surgery — salpingostomy (conservation of the tube after an ectopic), tubal ligation reversal, and fallopian tube reconstructive surgery all increase ectopic risk
Tubal ligation (sterilization) — paradoxically, if conception occurs after a failed or reversed tubal ligation, it is disproportionately likely to be ectopic
Assisted reproductive technology (ART) — IVF increases ectopic risk even with uterine embryo transfer because tubal dysfunction co-exists; heterotopic pregnancy (simultaneous intrauterine + ectopic) occurs in approximately 1 in 3,800 natural conceptions but in 1 in 100–500 IVF cycles
Intrauterine device (IUD) in situ — IUDs prevent intrauterine pregnancy very effectively; the rare pregnancy that occurs despite an IUD is more likely to be ectopic (though the absolute rate of ectopic with IUD in situ is lower than without contraception)
Endometriosis — tubal involvement or peritubal adhesions from endometriosis impede embryo transport
Smoking — nicotine impairs tubal cilia motility and smooth-muscle peristalsis; dose-dependent increase in ectopic risk
Age ≥ 35 — modest independent risk factor, possibly related to ciliation decline
Prior abdominal or pelvic surgery — appendectomy, myomectomy, colectomy — peritubal adhesions

Symptoms

Symptoms depend on whether the ectopic pregnancy has ruptured. Many women present before rupture with non-specific early pregnancy symptoms.

Before Rupture

Amenorrhea — missed period; the woman may or may not know she is pregnant
Unilateral pelvic or lower abdominal pain — often crampy or sharp; may be intermittent
Vaginal bleeding — typically lighter than a normal period; often described as brown spotting; does not reliably distinguish from threatened miscarriage
Pregnancy symptoms — breast tenderness, nausea, urinary frequency (hCG is present, just lower and rising more slowly than in intrauterine pregnancy)
Shoulder tip pain — referred pain from diaphragmatic irritation by small amounts of intraperitoneal blood; an early warning sign of leaking

At or After Rupture (Surgical Emergency)

Sudden severe lower abdominal or pelvic pain — often described as tearing or ripping
Signs of hemorrhagic shock — tachycardia, hypotension, pallor, diaphoresis, syncope
Peritoneal signs — guarding, rigidity, rebound tenderness
Cervical motion tenderness — on bimanual exam, mimicking PID
Cullen's sign — periumbilical ecchymosis from intraperitoneal hemoperitoneum (rare, late)

Diagnosis and the β-hCG Discriminatory Zone

Diagnosis rests on the combination of serum β-hCG levels and transvaginal ultrasound (TVUS). The key diagnostic concept is the discriminatory zone: the β-hCG threshold above which an intrauterine pregnancy (IUP) should be reliably visible on TVUS in a normal singleton pregnancy.

The β-hCG Discriminatory Zone

The traditional discriminatory zone is 1,500–2,000 mIU/mL with high-resolution TVUS; some institutions use 3,500 mIU/mL to reduce false-positive diagnosis of failing IUPs
When β-hCG is above the discriminatory zone and TVUS shows no intrauterine gestational sac, ectopic pregnancy must be presumed until proven otherwise
When β-hCG is below the discriminatory zone, serial measurements every 48 hours are used: a normal IUP rises ≥35% in 48 hours; a rise <35% or a plateau raises suspicion for ectopic or failing IUP; a β-hCG fall of ≥50% in 48 hours suggests spontaneous resolution (medical management may still be appropriate)

Transvaginal Ultrasound (TVUS)

Most useful single test; visualizes an intrauterine or extrauterine gestational sac, free fluid in the pelvis (hemoperitoneum), and adnexal masses
A tubal ring sign or extrauterine embryo with cardiac activity is diagnostic of ectopic (positive predictive value ~95%)
An empty uterus with a β-hCG above the discriminatory zone is highly suspicious; additional evaluation or empiric treatment is warranted

Uterine Curettage

When the location of pregnancy is uncertain and methotrexate is being considered, uterine curettage can distinguish a failing IUP (chorionic villi present) from ectopic (no villi); the absence of villi in evacuated tissue with a plateau or rising β-hCG is diagnostic of ectopic

Serum Progesterone

A single progesterone level <5 ng/mL is associated with a non-viable pregnancy (IUP or ectopic); >20 ng/mL suggests a viable IUP; levels 5–20 ng/mL are indeterminate. Useful as an adjunct, not a standalone test

Methotrexate Treatment

Methotrexate (MTX) is a folic acid antagonist that inhibits rapidly dividing trophoblast cells, causing the ectopic pregnancy to resorb. It is the mainstay of non-surgical management for appropriately selected patients.

Criteria for Methotrexate Eligibility (all must be met)

Hemodynamically stable (no rupture)
β-hCG ≤ 5,000 mIU/mL (higher levels have lower success rates; some guidelines allow up to 10,000 with two-dose protocol)
No fetal cardiac activity on TVUS
Ectopic mass ≤ 3.5–4 cm on TVUS
No contraindications: breastfeeding, immunodeficiency, blood dyscrasias, active pulmonary disease, hepatic or renal impairment, peptic ulcer disease, sensitivity to MTX
Reliable for follow-up (serial β-hCG monitoring is essential)

Dosing Protocols

Single-dose protocol — MTX 50 mg/m² IM on day 1; repeat if β-hCG does not fall ≥15% between day 4 and day 7; overall success rate 73–87%
Two-dose protocol — MTX on day 0 and day 4, higher success rate (~87%) for higher initial β-hCG levels
Multi-dose protocol — MTX on days 1, 3, 5, 7 alternating with leucovorin rescue; highest success rate (~90–93%) but more side effects

Side Effects and Monitoring

Separation pain — abdominal cramping on days 3–7 as the ectopic dies; patient should return to ED if pain is severe or unresponsive to oral analgesics
Nausea, stomatitis, conjunctivitis, photosensitivity (avoid sun during treatment)
Avoid folic acid supplements, NSAIDs, and alcohol during treatment
Avoid pregnancy for 3 months after MTX (teratogenic)
Repeat β-hCG weekly until undetectable; median time to resolution 14–21 days (occasionally 6–8 weeks with high initial levels)

Surgical Treatment

Surgery is indicated when methotrexate criteria are not met, when rupture has occurred or is imminent, when the patient is hemodynamically unstable, or when the patient prefers surgical management.

Salpingostomy

A linear incision is made over the ectopic pregnancy through the tube wall, the products of conception are removed, and the tube is left to heal by secondary intention (not sutured closed)
Preserves the fallopian tube — historically favored when the contralateral tube is absent or damaged
Disadvantage: persistent trophoblast occurs in 4–8% of cases (residual trophoblastic tissue continues producing hCG); serial β-hCG monitoring is mandatory post-operatively; MTX may be needed
Contemporary evidence suggests fertility outcomes after salpingostomy are not significantly better than after salpingectomy when the contralateral tube is healthy

Salpingectomy

Removal of the affected fallopian tube; the definitive treatment with no risk of persistent trophoblast
The ESEP trial (Fernandez et al., 2013) found that in women with a healthy contralateral tube, salpingectomy resulted in similar cumulative intrauterine pregnancy rates at 3 years as salpingostomy (57% vs 61%), supporting salpingectomy as the default when the contralateral tube appears normal
Total vs. partial salpingectomy: removal of the entire tube reduces future ectopic risk and the small risk of ipsilateral ovarian cancer (tubes are the origin of most high-grade serous ovarian cancers)

Laparoscopy vs. Laparotomy

Laparoscopy is the preferred surgical approach for stable patients: shorter hospital stay, less blood loss, faster recovery, equivalent success rates to laparotomy
Laparotomy is reserved for hemodynamic instability, massive hemoperitoneum, poor visualization, or surgeon inexperience with laparoscopic hemostasis in the unstable patient

Recovery and Supportive Care

Rh immunoglobulin (RhoGAM) — all Rh-negative women with ectopic pregnancy, regardless of treatment route, should receive 50–300 mcg anti-D immunoglobulin within 72 hours to prevent Rh sensitization in future pregnancies
Grief support — ectopic pregnancy is a pregnancy loss and often follows infertility treatment; acknowledge the loss directly; referral to a perinatal loss counselor or support group is appropriate
Contraception — ovulation may return as early as 2 weeks after ectopic resolution; contraception is needed until the couple is ready to try again (typically 3 months post-MTX to allow MTX clearance and folate replenishment)
Folic acid — 400–800 mcg daily starting 3 months after MTX completion before the next conception attempt; repletes stores depleted by MTX
STI screening and treatment — if prior PID or STI was the risk factor, thorough treatment of patient and partners before the next attempt is essential
Smoking cessation — strongly recommended given its dose-dependent effect on tubal cilia and ectopic recurrence risk
Early ultrasound in next pregnancy — given the 10–15% recurrence risk, transvaginal ultrasound at 5–6 weeks in the next pregnancy is standard practice to confirm intrauterine location before symptoms develop

Complications

Tubal rupture — the most feared complication; occurs in approximately 15–20% of women who present with symptoms before diagnosis; risk increases with tubal isthmic location (narrower segment) and larger ectopic mass
Hemorrhagic shock — rapid intraperitoneal hemorrhage after rupture; can cause death if not treated within minutes to hours
Persistent trophoblast — after salpingostomy (4–8%) or occasionally after MTX (5–10% require a second dose or surgery); requires close serial β-hCG monitoring
MTX side effects — elevation of liver transaminases (usually transient), bone marrow suppression (rare at single doses used for ectopic), mucositis, alopecia
Recurrent ectopic pregnancy — 10–15% risk after the first ectopic; increases with each subsequent episode
Loss of fallopian tube — after salpingectomy; reduces future spontaneous conception rates when the contralateral tube is also compromised
Psychological impact — anxiety, depression, and post-traumatic stress symptoms are common; the acute life-threatening nature of rupture adds trauma to grief

Arias-Stella Reaction

The Arias-Stella reaction is a benign, non-neoplastic histological change in endometrial glandular epithelium caused by elevated levels of human chorionic gonadotropin (hCG) — the same hormone produced by any viable pregnancy, whether intrauterine or ectopic. It is an important diagnostic pitfall.

Histology — large, hyperchromatic, pleomorphic nuclei bulging into glandular lumens ("hobnail" or "tombstone" appearance); intranuclear pseudoinclusions; mitotic figures may be present. The architecture is secretory, not malignant
Clinical significance — when endometrial curettage is performed to rule out intrauterine pregnancy in a woman with a possible ectopic, finding Arias-Stella reaction in the absence of chorionic villi confirms there is no IUP — supporting (but not proving) the diagnosis of ectopic pregnancy
Differential diagnosis — can be mistaken for clear-cell carcinoma or endometrial adenocarcinoma on endometrial biopsy if the clinical context of pregnancy is not communicated to the pathologist; always include pregnancy status and β-hCG level on pathology requisitions
Named for Javier Arias-Stella, Peruvian pathologist who described the reaction in 1954 after noting the characteristic nuclear changes in endometrium from women at high altitude (also in normal pregnancies)

Fertility After Ectopic Pregnancy

Reproductive prognosis after ectopic pregnancy depends primarily on the underlying cause (tubal health), treatment choice, and whether the contralateral tube is intact.

Cumulative IUP rates — approximately 65% of women achieve a subsequent IUP within 18 months of ectopic pregnancy treatment; women with a healthy contralateral tube fare best
Salpingectomy vs salpingostomy — with a healthy contralateral tube, ESEP trial data show equivalent 3-year IUP rates (57–61%); when the contralateral tube is absent or severely damaged, tube conservation (salpingostomy) is strongly preferred to preserve any chance of natural conception
IVF after ectopic — excellent outcomes, particularly after salpingectomy; live-birth rates per cycle comparable to tubal factor infertility from other causes; heterotopic pregnancy risk in IVF warrants TVUS at 5–6 weeks post-transfer
Prognostic factors for recurrence — prior PID, bilateral tubal disease, smoking history, and age ≥35 are the main independent predictors of recurrent ectopic; counseling before the next conception attempt should address modifiable factors

Prognosis

Prognosis is excellent when ectopic pregnancy is diagnosed before rupture. Ruptured ectopic pregnancy remains a surgical emergency with significant maternal mortality risk in resource-limited settings or with delayed presentation.

In countries with access to early transvaginal ultrasound and sensitive β-hCG assays, most ectopics are now diagnosed before rupture and treated with MTX or laparoscopic surgery
The 3-year cumulative IUP rate after a first ectopic is approximately 65%, rising to >80% in women with an intact contralateral tube
Women with recurrent ectopic or bilateral tubal loss should be counseled that IVF bypasses the tubes entirely and offers comparable per-cycle pregnancy rates to unexplained infertility
Psychological recovery is often underestimated; many women experience significant grief, anxiety, and relationship strain; structured psychological support improves outcomes

Key Research Papers

Barnhart KT, Sammel MD, Gracia CR, Chittams J, Hummel AC, Shaunik A. Risk Factors for Ectopic Pregnancy in Women with Symptomatic First-Trimester Pregnancies. Fertility and Sterility. 2006;86(1):36–43. PMID 16730720.
Barnhart KT. Ectopic Pregnancy. New England Journal of Medicine. 2009;361(4):379–387. PMID 19625718.
Fernandez H, Capmas P, Lucot JP, Resch B, Panel P, Bouyer J; GROG Group. Fertility After Ectopic Pregnancy: The DEMETER Randomized Trial. Human Reproduction. 2013;28(5):1247–1253. PMID 23482501.
Mol F, van Mello NM, Strandell A, et al. Salpingotomy versus Salpingectomy in Women with Tubal Pregnancy (ESEP Study): An Open-Label, Multicentre, Randomised Controlled Trial. Lancet. 2014;383(9927):1483–1489. PMID 24210711.
Barnhart K, Sammel MD, Chung K, Zhou L, Hummel AC, Guo W. Decline of Serum Human Chorionic Gonadotropin and Spontaneous Complete Abortion: Defining the Normal Curve. Obstetrics & Gynecology. 2004;104(5 Pt 1):975–981. PMID 15516387.
American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 193: Tubal Ectopic Pregnancy. Obstetrics & Gynecology. 2018;131(3):e91–e103. PMID 29470343.
Goldner TE, Lawson HW, Xia Z, Atrash HK. Surveillance for Ectopic Pregnancy — United States, 1970–1989. MMWR CDC Surveill Summ. 1993;42(6):73–85. PMID 8474420.
Seeber BE, Barnhart KT. Suspected Ectopic Pregnancy. Obstetrics & Gynecology. 2006;107(2 Pt 1):399–413. PMID 16449130.
Lipscomb GH, Stovall TG, Ling FW. Nonsurgical Treatment of Ectopic Pregnancy. New England Journal of Medicine. 2000;343(18):1325–1329. PMID 10922425.
Clayton HB, Schieve LA, Peterson HB, Jamieson DJ, Reynolds MA, Wright VC. Ectopic Pregnancy Risk with Assisted Reproductive Technology Procedures. Obstetrics & Gynecology. 2006;107(3):595–604. PMID 16507931.
Shaw JL, Oliver EC, Lee KA, et al. Cotinine Exposure Increases Fallopian Tube PROKR1 Expression via Nicotinic AChRalpha-7: A Potential Mechanism Explaining the Link Between Smoking and Tubal Ectopic Pregnancy. American Journal of Pathology. 2010;177(5):2509–2515. PMID 20833899.
Arias-Stella J. The Arias-Stella Reaction: Facts and Fancies Four Decades After. Advances in Anatomic Pathology. 2002;9(1):12–23. PMID 11917179.

PubMed Topic Searches

Back to Table of Contents

Connections